Stay updated on NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial

Sign up to get notified when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a shift in the survival duration comparison between different treatment options for non-squamous NSCLC patients, specifically involving the addition of atezolizumab to the treatment regimen.
    Difference
    0.1%
    Check dated 2024-06-06T14:22:50.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    62%
    Check dated 2024-05-22T20:23:34.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:01:54.000Z thumbnail image

Stay in the know with updates to NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.